Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Total revenue by Year
Total revenue — International (pre-2021 legacy grouping) ($M) ($M)
Moderna Total revenue: $38.9M in FY2020, up 648.1% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2020
38.9
Period ended Dec 31, 2020
Change on a year earlier
+648.1%
5.20 in FY2019
History
3 years
Since FY2018
Sources
1
Form 10-K (filed 2021-02-26)
Where the FY2020 figure comes from
Source: Form 10-K (filed 2021-02-26) ↗
Reported in Form 10-K Geographic Information.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total revenue — International (pre-2021 legacy grouping) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2020 | Dec 31, 2020 | 38.9 | +648.1% | Form 10-K (filed 2021-02-26) ↗ |
| FY2019 | Dec 31, 2019 | 5.20 | -88.7% | Form 10-K (filed 2021-02-26) ↗ |
| FY2018 | Dec 31, 2018 | 46 | – | Form 10-K (filed 2021-02-26) ↗ |
Cite this data
StockData. (2026). Moderna Total revenue ($M), annual FY2018–FY2020 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rev-geo-nonus-legacy
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.